UK cost watch­dog drafts guid­ance against 5 Covid treat­ments and J&J de­pres­sion med

It looks like five Covid treat­ments like­ly won’t make the NICE list this year, the UK’s cost-ef­fec­tive­ness watch­dog re­cent­ly an­nounced, and nei­ther will J&J’s es­ke­t­a­mine.

The coun­try’s Na­tion­al In­sti­tute for Health and Care Ex­cel­lence, which ad­vis­es the Na­tion­al Health Ser­vice, re­leased draft guid­ance on Wednes­day that rec­om­mends against Re­gen­eron’s mon­o­clon­al an­ti­body com­bo Re­gen-Cov (al­so known as casiriv­imab and imde­vimab), GSK’s Xe­vudy (sotro­vimab), and As­traZeneca’s Evusheld (tix­agevimab and cil­gav­imab) due to un­cer­tain­ty over just how ef­fec­tive they are against Omi­cron.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.